Effective variant of type 2 diabetes mellitus treatment
Background. The purpose was to evaluate the efficiency of phytoextract Ferment S6 as a part of comprehensive therapy in patients with type 2 diabetes mellitus (DM). Materials and methods. Thirty patients with type 2 DM and dyslipidemia were under observation. Duration of type 2 DM was from 8 to 25 years, average age of patients — 39.5 ± 6.7 years. All patients received Ferment S6 phytoextract (one capsule after breakfast) in addition to combination treatment. Duration of follow-up was 3 months. Patients underwent laboratory and instrumental examination. Results. As a result of Ferment S6 phytoextract addition to the comprehensive DM therapy, there was a positive dynamics of somatic signs. The improvement of carbohydrate and lipid exchanges is marked, and also indexes of the functional state of the liver. The clinical safety of preparation was determined on the basis of subjective symptoms reported by patients (in the process of supervision — 2 visits during three months), objective data, and laboratory indexes in dynamics (at the beginning of research and on a final visit). The analysis of tolerability of the drug during comprehensive therapy showed that in 100 % of cases it was good. Conclusions. After treatment with inclusion of phytoextract Ferment S6, there was marked a decrease in subjective asthenic, somatic and vegetative disorders as a reduction in the degree of severity of headache, irritability, general weakness, improvement of quality of life. The most significant changes were: an increase in working capacity and tolerance to physical activity, which increased the adherence of patients to the observance of a lifestyle with type 2 DM. Phytoextract Ferment S6 is well tolerated by patients and does not cause side effects with prolonged use.
Full Text:PDF (Русский)
American Diabetes Association. Standards of medical care in diabetes - 2017: Promoting Health and Reducing Disparities in Populations. Diabetes Care. 2017 Jan; 40(Suppl 1):S6-S10. doi: 0.2337/dc17-S004.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary. Endocr Pract. 2017 Feb;23(2):207-238. doi: 10.4158/EP161682.CS.
Cho NH, Kirigia J, Mbanya JC, et al, editors. IDF Diabetes Atlas - 8thEdition. 2017. Available from: http://www.diabetesatlas.org/resources/2017-atlas.html.
Bergmark BA, Bhatt DL, Braunwald E, et al. Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. Diabetes Care. 2018 Mar;41(3):577-585. doi: 10.2337/dc17-1736.
Basu S, Raghavan S, Deborah J, Wexler DJ. Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial. Diabetes Care. 2018 Mar;41(3):604-612. doi: 10.2337/dc17-2252.
Nielsen J, Hulman A, Witte DR. Spousal cardiometabolic risk factors and incidence of type 2 diabetes: a prospective analysis from the English Longitudinal Study of Ageing. Diabetologia. 2018 Mar 8. doi: 10.1007/s00125-018-4587-1. [Epub ahead of print].
Huo L, Magliano DJ, Rancière F, et al. Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997-2011. Diabetologia. 2018 May;61(5):1055-1063. doi: 10.1007/s00125-018-4544-z.
Wilmot EG, Edwardson CL, Achana FA, et al. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia. 2012 Nov;55(11):2895-905. doi: 10.1007/s00125-012-2677-z.
Raman R, Gupta A, Krishna S, Kulothungan V, Sharma T. Prevalence and risk factors for diabetic microvascular complications in newly diagnosed type II diabetes mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 27). J Diabetes Complications. 2012 Mar-Apr;26(2):123-8. doi: 10.1016/j.jdiacomp.2012.02.001.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2018